Satellite Symposium of the EAS 76^th Congress

and the XVth Paavo Nurmi Symposium

 

HIGH DENSITY LIPOPROTEINS

AND ATHEROSCLEROSIS

June 7-9, 2007
in Helsinki, Finland

PROGRAM

General Info

Registration

Abstract Submission

Symposium

Location

NEXT

BACK

THURSDAY, JUNE 7^th, 2007

 

15.00-19.00        Arrival and registration

19.00-23.00        Get-together party at the Biomedicum Helsinki           

 

 

FRIDAY, JUNE 8^th, 2007

 

08.30-08.45        Opening remarks

08.45-09.00        Paavo Nurmi Foundation presents
                          a short documentary film

 

SESSION I  

HDL STRUCTURE AND FUNCTIONS

Chairpersons: Kerry-Ann Rye and Matti Jauhiainen

 

09.00-09.45        Prof. SEAN DAVIDSON, U. of Cincinnati, USA:

                          ”Apolipoprotein A-I; Belts, bundles, hinges and hairpins ”

09.45-10.30        Prof. VASSILIS ZANNIS, Boston U, USA:

                          ”Discrete Roles of ApoA-I and ApoE in the Biogenesis of HDL                           Species: Lessons Learned from Gene Transfer Studies in                                 Different Mouse Models.”

 

10.30-11.00        Coffee

 

11.00-12.00        Abstract presentations:

 

             11.00-11.30 ”Exploring the Crystal Structure of Cholesteryl Ester
             Transfer Protein” XIA YANG QIU, Pfizer Inc, USA

             11.30-11.45 ”Structural modifications of HDL by secretory
             sphingomyelinase have opposing effects on SR-BI and ABCA1-
             mediated cholesterol efflux” MICHEL MARCIL, McGill U Health
             Center, Canada

             11.45-12.00 ”Molecular basis of the suppression of reperfusion-
             induced arrhythmias by ApolipoproteinA-I discs” SCIN-ICHIRO
             MIURA, U. of Fukuoka, Japan

 

12.00-13.00        Lunch

13.00-14.00        Posters

 

SESSION II  

HDL AND CELLULAR METABOLISM

Chairpersons Arie van Tol and Petri Kovanen

 

14.00-14.30        Prof. SHINJI YOKOYAMA, Nagoya City U, Japan:

                          ”Assembly of high-density lipoprotein by the ABC
                          transporter/apolipoprotein pathway ”

14.30-15.00        Prof. JACQUES GENEST, McGill U, Montreal, Canada:

                          ”Modern focus into the biogenesis of human high-density                                lipoproteins ”

15.00-15.30        Prof. YVES L. MARCEL, U. of Ottawa Heart Inst, Canada:

                          ”The hepatic pathway of high-density lipoprotein formation”

 

15.30-16.45        Abstract presentations:

 

             15.30-15.45 ”OSBP-Related Protein 8 modulates the                                           transcriptional control of cellular sterol homeostasis” V.M.                               OLKKONEN, National Public Health Institute, Finland

             15.45-16.00 ”Role of ABCA1 in the regulation of cholesterol                              homeostasis in macrophages” O.L. FRANCONE, Pfizer Inc, USA

             16.15-16.30 ”Defective adrenal HDL-cholesterol ester uptake via                      scavenger receptor impairs (hepatic) corticosteroid signalling                        and induces fasting hypoglycaemia in mice” MENNO HOEKSTRA,                  Leiden/Amsterdam Center for Drug Research, Netherlands

             16.30-16.45 ”In vivo HDL catabolism: a novel experimental                               approach using fluorescently labeled HDL in their lipid and                              protein moieties” ATHINA KALOPISSIS, INSERM, France

 

19.30-22.00        Symposium Dinner

 

            
SATURDAY, JUNE 9^th, 2007

SESSION III  

HDL AND ATHEROSCLEROSIS

Chairpersons Miranda van Eck and Vesa Olkkonen

 

09.00-09.45        Prof. PHIL BARTER, The Heart Research Inst, Sydney, Australia

                          ”The role of high density lipoproteins in reducing cardiovascular                           risk ”

09.45-10.30        Prof. H. BRIAN BREWER JR, National Heart, Lung and Blood

                          Inst. / NIH, Bethesda, USA:

                          ”The ABCs of high-density lipoprotein metabolism”

 

10.30-11.00        Coffee

 

11.00-12.00        Abstract presentations:

 

             11.00-11.15 ”Combined deletion of SR-BI and ABCA1 in                                    macrophages dramatically enchances macrophage foam cell                          information and atherosclerotic lesion development” MIRANDA                      van ECK, Leiden/Amsterdam Center for Drug Research, NL

             11.15-11.30 ”HDL2 mediated cholesterol efflux from human                              monocyte-derived macrophages is associated with severity of                        coronary artery disease independent of plasma HDL” P. LINSEL-                    NITSCHKE, U. of Lübeck, Germany

             11.30-11.45 ”High plasma cholesteryl ester transfer protein mass may              favour reduced incidence of cardiovascular disease in men with low              trigclycerides” R.P. DULLAART, U. Medical Center Groningen, NL

             11.45-12.00 ”Effects of smoking and obesity on exercise-induceed HDL              elevation” MASATSUNE OGURA, National Defence Medical College

 

12.00-13.00        Lunch

13.00-14.00        Posters

 

SESSION IV  

HDL - CLINICAL ASPECTS

Chairpersons John Chapman and Christian Ehnholm

 

14.00-14.45        Prof. CESARE SIRTORI, U. of Milan, Italy:

                          ”ApoA-I Milano; From structure to clinical applications ”

14.45-15.30        Prof. JEAN-CHARLES FRUCHART, Institut Pasteur, Lille, France:

                          ”Therapeutic strategies for high-density lipoprotein elevation”

 

15.30-16.00        Coffee

 

16.00-17.00        Abstract presentations:

 

             16.00-16.15 ”Niacin receptor pharmacology and its role in the anti-

             atherosclerotic effects of niacin” M. GERARD WATERS, Merck Research

             Laboratories, USA

             16.15-16.30 ”Mutations in ABCA1, low HDL, and risk of ischemic heart              disease” R. FRIKKE-SCHMIDT, U of Copenhagen, Denmark

             16.30-16.45 ”Myeloperoxidase is associated with in vivo oxidized LDL in               individuals with low HDL-cholesterol concentration” L.P. van DER ZWAN,              VU U. Medical Center, NL

             16.45-17.00 ”Functionally defective HDL in type 2 diabetes: impact of              dyslipidemia and hyperglycemia” M.J. CHAPMAN, INSERM, France

            

 

17.00-17.15        Closing remarks—the satellite ends

 

Program